Aaron Cowen’s Apellis Pharmaceuticals APLS Stock Holding History

Aaron Cowen’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,518,471	Closed	-$142M	–	97
2026 Q1	$142M	Sell	3,518,471 -620,955	-15%	-$13.4M	3.62%	5
2025 Q4	$104M	Buy	4,139,426 +1,261,426	+44%	+$29.6M	2.13%	11
2025 Q3	$65.1M	Hold	2,878,000	–	–	1.67%	19
2025 Q2	$49.8M	Buy	2,878,000 +1,231,385	+75%	+$22.8M	1.5%	24
2025 Q1	$36M	Buy	1,646,615 +853,428	+108%	+$23.6M	1.34%	24
2024 Q4	$25.3M	Buy	+793,187	New	+$23.9M	0.86%	39
2020 Q2	–	Sell	-21,600	Closed	-$579K	–	81
2020 Q1	$579K	Buy	+21,600	New	+$767K	0.02%	60

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Aaron Cowen's APLS Position: Q2 2026 in Review

Aaron Cowen sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 3,518,471 shares — an estimated $142M sold.

Aaron Cowen first reported a position in APLS in Q1 2020 and held it in 7 quarters. The position peaked at $142M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Aaron Cowen reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Aaron Cowen sold 3,518,471 Apellis Pharmaceuticals shares in Q2 2026, an estimated $142M.
Aaron Cowen first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 7 quarters.
Aaron Cowen's Apellis Pharmaceuticals position peaked at $142M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.